HAS Healthcare Advanced Synthesis Participates in DCAT Sustainability Summit: The Global Bio/Pharmaceutical Sustainability Imperative Summit, on May 22nd, 2024, in Lugano, Switzerland

Biasca, Switzerland, May 22, 2024

We are delighted to actively participate in the DCAT Sustainability Summit: The Global Bio/Pharmaceutical Sustainability Imperative Summit, hosted at the Convention Center in Lugano, Switzerland.

Dr. Waldo Mossi, Chief Executive Officer at HAS Healthcare Advanced Synthesis (HAS), Switzerland, together with other leading executives, will be a featured speaker in the session “CEO’s Unplugged Roundtable”, which will be held on Wednesday May 22nd, 2024, at 3.15pm.

In this session, C-suite executive leaders will discuss the critical role of sustainability in driving business success. They will explore how sustainability impacts shareholder value, reporting obligations, investment strategies, credit and risk profiles, funding strategies, supply chain optimization and compliance priorities.

As a company committed to driving positive change, HAS recognizes the urgency of addressing sustainability challenges in our industry. Dr. Waldo Mossi’s participation in this event underscores our commitment to sustainability and our belief that businesses play a pivotal role in shaping a more sustainable future.

The DCAT Global Bio/Pharmaceutical Sustainability Summit represents a critical opportunity to collaborate, learn, and accelerate positive change. HAS looks forward to engaging with fellow leaders who share our vision.


About HAS Healthcare Advanced Synthesis

HAS Healthcare Advanced Synthesis is a CDMO that offers a full range of customized services from laboratory development to manufacturing. HAS Healthcare Advanced Synthesis develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, high-activity active pharmaceutical ingredients (HPAPIs) and anticancer compounds.

The production facility is located in Biasca, Switzerland, and was founded in 1984. The site is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. The production scale ranges from a few hundred grams to tens of kilograms for highly active ingredients (HPAPI) and anticancer and from kilograms to tens of tons for standard active ingredients (APIs); the plants are completely dedicated to cGMP production.

For more information visit our website https://www.hashealthcare.com/ and follow us on Linkedin.

Contact Press Office

HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: [email protected]